Silexion Therapeutics (NASDAQ:SLXN) Releases Quarterly Earnings Results, Beats Expectations By $16.03 EPS

Silexion Therapeutics (NASDAQ:SLXN) issued its quarterly earnings results on Friday. The company reported ($5.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03, FiscalAI reports.

Silexion Therapeutics Price Performance

NASDAQ SLXN opened at $0.42 on Friday. Silexion Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $80.00. The stock’s 50-day moving average is $2.42 and its two-hundred day moving average is $8.52. The firm has a market cap of $176,063.80, a P/E ratio of -0.01 and a beta of -0.25.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Maxim Group downgraded Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Silexion Therapeutics has an average rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.